Clinical trial
A Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475.
NCT02303366 is registered in ClinicalTrials.gov with Peter MacCallum Cancer Centre, Australia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475.
- Lead sponsor
- Peter MacCallum Cancer Centre, Australia
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2015
- Completion date
- April 30, 2017
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.